Sanofi and Regeneron are gearing up to file their experimental PD-1 inhibitor cemiplimab on both sides of the Atlantic following the drug’s success in clinical trials.
News
Real world data back use of Eisai, Bial’s Zebinix in epilepsy
A pooled analysis of real-world data from over 2,000 patients with epilepsy has shown that Eisai and Bial’s Zebinix is safe and effective when switching from previous treatment with carbamazepine or oxcarbazepine.
Pharma companies fall foul of ABPI’s Code of Practice
Sunovion Pharmaceuticals Europe, Bayer, Astellas UK, Astellas Europe and Menarini Pharma UK SRL have been named in adverts for breaching of the ABPI’s Code of Practice.
Vernalis, Daiichi Sankyo work together on new cancer targets
UK drugmaker Vernalis has signed a drug discovery deal with Daiichi Sankyo Co that aims to find new targets for potential cancer therapies.
Pharma companies fall foul of ABPI’s Code of Practice
Sunovion Pharmaceuticals Europe, Bayer, Astellas UK, Astellas Europe and Menarini Pharma UK SRL have been named in adverts for breaching of the ABPI’s Code of Practice.
FDA OK’s GSK’s asthma biologic for rare autoimmune disease
GlaxoSmithKline’s biologic Nucala has become the first therapy specifically approved in the US to treat a rare disease called eosinophilic granulomatosis with polyangiitis (EPGA).
UK hospital combines gaming and AR for patient care app
Alder Hey Children’s Hospital launches its Alder Play iPhone and Android app.
J&J’s Darzalex shows promise in newly-diagnosed multiple myeloma
Johnson & Johnson group Janssen has unveiled new data showing a 50 percent cut in the risk of disease progression or death in patients with newly diagnosed multiple myeloma given Darzalex on top of standard treatment.
Medherant raises £3.8 million for transdermal patch
Coventry, UK-based Medherant has raised £3.8 million in its latest funding round to help further development of its ibuprofen TEPI Patch.
US clears Sanofi’s ‘follow-on’ insulin Admelog
The US Food and Drug Administration has cleared Sanofi’s Admelog, the first follow-on biologic version of Eli Lilly’s Humalog, to manage mealtime blood sugar levels in people with diabetes.
Scotland approves NHS funding for Ibrance, Cerdelga and Invicorp
The latest batch of decisions by the Scottish Medicines Consortium has given patients with certain forms of breast cancer, Gaucher disease and erectile dysfunction new treatment options on the NHS.
Final NHS ‘no’ for obesity pill Mysimba
An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, with cost-regulators publishing final guidelines rejecting the drug.
Lilly files anti-CGRP drug for migraine
US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of migraine.
Novartis’ Kymriah shows durable response in blood cancer
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
NICE u-turn backs combo for kidney cancer
In a turnaround from its earlier position, the National Institute for Health and Care Excellence is now endorsing NHS funding for Eisai’s Kisplyx plus everolimus for kidney cancer.
